Dulaglutide Provides CVD Protection with or without Metformin 

Data from the REWIND trial suggest that dulaglutide has cardioprotective properties. 

Cardiovascular events in individuals with type 2 diabetes are approximately twice as prevalent as in individuals without type 2 diabetes. Data from the REWIND trial suggest that dulaglutide has cardioprotective properties. 

The study aimed to analyze the cardiovascular benefit of dulaglutide in patients with type 2 diabetes, regardless of whether the patient has been on metformin therapy. The REWIND trial was a multicentered, randomized, double-blinded trial. The Cox regression model was also used. This model is used to show the probability of a particular event to occur at a specific time....

Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.